Jasper Therapeutics
JSPR
45 hedge funds and large institutions have $5.05M invested in Jasper Therapeutics in 2026 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 14 reducing their positions, and 16 closing their positions.
455% more call options, than puts
Call options by funds: $122K | Put options by funds: $22K
13.66% less ownership
Funds ownership: 56.51% → 42.85% (-14%)
22% less funds holding
Funds holding: 58 → 45 (-13)
36% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 14
64% less capital invested
Capital invested by funds: $13.9M → $5.05M (-$8.81M)
81% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$386K |
| 2 |
Jane Street
New York
|
+$60.1K |
| 3 |
Renaissance Technologies
New York
|
+$45.2K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$25.2K |
| 5 |
JG
Jain Global
New York
|
+$24.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$997K |
| 2 |
Millennium Management
New York
|
-$846K |
| 3 |
BFM
Boothbay Fund Management
New York
|
-$511K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$282K |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$242K |
JSPR Hedge Fund Activity: Q2 2026 in Review
45 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q2 2026, worth a combined $5.05M — down 64% from $13.9M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of JSPR and 3 opened new positions — a net loss of 13 holders — while 14 trimmed existing stakes and 9 added.
The largest buyer was GSA Capital Partners, adding an estimated $386K. The largest seller was Morgan Stanley, cutting an estimated $997K.
- 45 institutional investors held Jasper Therapeutics (JSPR) as of Q2 2026, down from 58 in Q1 2026.
- Funds reported $5.05M of Jasper Therapeutics stock for Q2 2026, down 64% quarter-over-quarter.
- 3 funds opened new Jasper Therapeutics positions in Q2 2026 and 16 closed out, a net change of -13 holders.
- The largest Jasper Therapeutics buyer in Q2 2026 was GSA Capital Partners, an estimated $386K added.
- The largest Jasper Therapeutics seller in Q2 2026 was Morgan Stanley, an estimated $997K sold.
Based on aggregated 13F filings for Q2 2026.